



## David Michael Asmuth, M.D.

**Philosophy of Care** Dr. Asmuth's philosophy of care is based on patient autonomy and providing a proactive approach to medical therapy. He seeks to provide information to the patient in a partnership that focuses on maintaining health and limiting the long-term consequences of chronic infections, especially HIV and HCV.

**Clinical Interests** Dr. Asmuth has had over 25 years experience treating patients with general infectious diseases with a focused interest in HIV/AIDS and HIV/HCV coinfection. He also treats patients with HCV infection alone.

Dr. Asmuth has conducted approximately 100 clinical trials in the treatment of HIV/AIDS, HIV/HCV coinfection, and HCV monoinfection over the last twenty-five years of clinical research. He has a special interest in translational research trials that focus on HIV pathogenesis, immune reconstitution following initiation of anti-HIV medications, and the impact of HIV infection on mucosal immunity in the gastrointestinal tract. He has recently directed attention to host-microbiome interactions in HIV enteropathy and their effects on systemic immune activation. In addition, he has written and conducted clinical trials for the development of preventive and therapeutic vaccines for HIV, immune-based therapies, and is collaborating with researchers exploring the role of stem cell approaches for the treatment of HIV.

**Title** Professor of Medicine

**Specialty** Infectious Diseases, Internal Medicine

**Department** [Internal Medicine](#)

**Division** Infectious Diseases

**Center/Program Affiliation** [Pacific AIDS Education and Training Center](#)

**Address/Phone** CARES Clinic, 1500 21st St. Sacramento, CA 95817  
**Phone:** 800-2-UCDAVIS

**Education** M.D., Northwestern University, Chicago, Illinois, 1985  
B.A., University of Notre Dame, South Bend, Indiana, 1977

**Internships** University of Wisconsin Hospital and Clinics, Madison, Wisconsin, 1985-1986

**Residency** Primary Care/Boise Tract, University of Washington at Seattle, Seattle, Washington, 1986-1988



## David Michael Asmuth, M.D.

**Fellowships** Deaconess Hospital/Harvard Medical School, Boston, Massachusetts, 1989-1993  
University of Washington-Seattle, Boise, Idaho, 1988-1989

**Board Certifications** American Board of Internal Medicine, 1988  
American Board of Internal Medicine, Infectious Disease, 1992

**Professional Memberships** American College of Physicians  
Infectious Diseases Society of America  
International Society of Analytical Cytometry  
Veterans Administration Northern California Health Care System-Associate Chief of Staff for Research and Development

**Honors and Awards** Nominated for Excellence in Teaching Award - Department of Internal Medicine - UTMB, 1999  
Humanism in Medical Education Award - AAMC UTMB nominee, 1999

**Select Recent Publications** Asmuth DM, Pinchuk IV, Wu J, Vargas G, Chen X, Mann S, Albanese A, Ma Z-M, Saroufeem R, Melcher GP, Troia-Cancio P, Torok NJ, Miller CJ, Powell DW. Role of Intestinal Myofibroblasts in HIV-1 Associated Intestinal Collagen Deposition and Immune Reconstitution following combination antiretroviral therapy. *AIDS* 2015 May 15;29(8):877-88.

Balagopal A, Asmuth DM, Yang W-T, Campbell TB, Gupta N, Smeaton L, Kenyama C, Grinsztejn B, Santos B, Supparatpinyo K, Badal-Faesen S, Lama JR, Lalloo U, Zulu F, Pawar JS, Riviere C, Kumarasamy N, Hakim J, Li X-D, Pollard RB, Semba RD, Thomas DL, Bollinger RC, Gupta A. Pre-cART Elevation of CRP and CD4+ T-cell Immune Activation Associated with HIV Clinical Progression in a Multinational Case-Cohort Study. *J Acquir Immune Defic Syndr*. May 2015

Rockstroh, Soriano V, Plonski F, Bansal M, Fätkenheuer G, Small CB, Asmuth DM, Pialoux G, Mukwaya G, Jagannatha S, Heera J, Pineda JA. Hepatic Safety in Subjects With HIV-1 and Hepatitis C and/or B Virus: A Randomized, Double-Blind Study of Maraviroc vs Placebo in Combination With Antiretroviral Agents. *HIV Clin Trials*. 2015 Mar-Apr;16(2):72-80.

Katsounas A, Frank AC, Lempicki RA, Polis MA, Asmuth DM, Kottitil S. Differential Specificity of Interferon-alpha Inducible Gene Expression in Association with Human Immunodeficiency Virus and Hepatitis C Virus Levels and Declines in vivo. *J AIDS Clin Res* 2015, 6:1.



## David Michael Asmuth, M.D.

Tenfordi MW, Gupte N, Dowdy DW, Asmuth DM, Balagopal A, Pollard RB, Sugandhavesa P, Lama J, Pillay S, Cardoso SW, Pawar J, Santo B, Riviere C, Mwelase N, Kanyama C, Dumwenda J, Hakim JG, Kumarasamy N, Bollinder R, Semba RD, Campbell TB, Gupta A. C-reactive protein, interferon gamma-inducible protein 10, and lipopolysaccharide are associated with risk of tuberculosis after initiation of antiretroviral therapy in resource-limited settings. *PLoS One*; 2015 Feb 26;10(2).

Grant PM, Komarow L, Sanchez A, Sattler FR, Asmuth DM, Pollard RB, Zolopa AR. Clinical and Immunologic Predictors of Death During an Acute Opportunistic Infection: Results from ACTG A5164. *HIV Clin Trials*. 2014 Jul-Aug;15(4):133-9.

Sulkowski MS, Naggie S, Lalezari J, Fessel WJ, Mounzer W, Shuhart M, Luetkemeyer AF, Asmuth D, Gaggar A, Ni L, Svarovskaia E, Brainard DM, Symonds WT, Subramanian GM, McHutchison JG, Rodriguez-Torres M, Dieterich D, for the PHOTON-1 Investigators. Sofosbuvir and Ribavirin for Hepatitis C in Patients With HIV Coinfection. *JAMA* 2014;312(4):353-361.

Pollard RB, Rockstroh JK, Pantaleo G, Asmuth DM, Peters B, Lazzarin A, Gatell J, Ellefsen-Lavoie K, Podzamczar D, van Lunzen J, Arastéh K, Schürmann D, Clotet B, Hardy D, Mitsuyasu R, Moyle G, Plettenberg A, Fisher M, Fätkenheuer G, Fischl M, Taiwo B, Baksas I, Jolliffe D, Persson S, Jelmert Ø, Hovden A-O, Sommerfelt MA, Wendel-Hansen V, Sørensen B. The safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4x: a randomised, double-blind, placebo-controlled phase 2 trial. *Lancet Infect Dis*. 2014 Apr;14(4):291-300.

Rodriguez B, Asmuth DM, Matining R, Spritzler J, Jacobson J, Mailliard R, Li X-D, Read S, Martinez A, Tenorio A, Lori F, Lisiewicz J, Yesmin S, Rinaldo CR, Pollard R. Safety, Tolerability and Immunogenicity of Repeated Doses of DermaVir, a Candidate Therapeutic HIV Vaccine, in HIV Infected Patients Receiving Combination Antiretroviral Therapy. Results of the ACTG 5176 Trial. *J Acquir Immune Defic Syndr* 2013 Dec 1;64(4):351-9.



## David Michael Asmuth, M.D.

Maniar A, Ellis CE, Asmuth D, Pollard RB, Rutledge J. HIV Infection and Atherosclerosis: Evaluating the Drivers of Inflammation. *Eur J Prev Cardiol.* 2013. Oct;20(5):720-8.

© 2017 UC Regents